Teva Embarks on Acceleration Phase of “Pivot to Growth” Strategy at 2025 Innovation & Strategy Day, Signaling Renewed Focus on Biopharmaceutical Leadership and Long-Term Shareholder Value Teva Pharmaceutical Industries Ltd.one of the world’s leading manufacturers of generic and specialty medicines,…
China Accepts New Drug Application for Shionogi’s Naldemedine to Treat Opioid-Induced Constipation Shionogi & Co., Ltd., a leading Japanese pharmaceutical company headquartered in Osaka, has announced a key regulatory milestone for its gastrointestinal therapeutic, naldemedine tosilate. The New Drug Application…
Astellas Secures Global Rights to Evopoint’s Promising CLDN18.2-Targeting Antibody-Drug Conjugate XNW27011 in Strategic Oncology Expansion In a strategic move that reinforces its commitment to precision oncology, Astellas Pharma Inc. has entered into an exclusive license agreement with Evopoint Biosciences Co.,…
Intellia Grapples with Safety Questions in ATTR Gene Editing Trial Amid Broader Sector Scrutiny Intellia Therapeutics’ stock took a steep dive Thursday morning, shedding approximately 26% of its value after the company disclosed a serious adverse event in its ongoing…
CVS Health Files Federal Lawsuit to Halt Arkansas’ Act 624, Citing Harm to Patients, Jobs, and Healthcare Access On May 29, 2025, CVS Health® filed a federal lawsuit seeking to overturn Arkansas’ controversial Act 624, a newly enacted law that…
Beyfortus Shows Stronger Public Health Impact Than Maternal RSV Vaccine in Landmark Real-World Comparison In a pivotal step forward for infant respiratory health, new real-world data from an immunization program in Spain reveal that Beyfortus® (nirsevimab), a long-acting monoclonal antibody…
Member States Officially Endorse World Prematurity Day as a Global Health Campaign at the 78th World Health Assembly At the recently concluded 78th World Health Assembly (WHA), a historic and decisive step was taken by the global health community: Member…
WHO Launches Comprehensive Framework Addressing the Intersection of Climate Change and Tuberculosis In a decisive move to confront two of the world’s most pressing public health challenges, the World Health Organization (WHO) has released a comprehensive new framework highlighting the…
Halozyme and Bristol Myers Squibb Secure European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE in Multiple Solid Tumors Halozyme Therapeutics celebrates a significant regulatory milestone as Bristol Myers Squibb gains European Commission approval for a new subcutaneous formulation of…
BeOne Medicines Officially Launches Following Redomiciliation to Switzerland, Ushering in a New Era of Global Oncology Leadership BeOne Medicines Ltd. formerly known as BeiGene, Ltd., has officially entered a transformative new chapter in its corporate journey with the announcement of…
BioNTech to Showcase Broad Advancements in Oncology Pipeline at 2025 ASCO Annual Meeting BioNTech ,a global biotechnology company known for pioneering mRNA-based technologies, announced that it will present significant clinical trial data from its diversified oncology pipeline at the 2025…
Pharma Doubles Down on R&D Amid Global Headwinds, Eyes Nearly $340 Billion in Investment by 2030 Despite formidable political and economic challenges ranging from inflation and rising operational costs to geopolitical instability and regulatory pressures, the global pharmaceutical industry continued…